|
02 Aug 2019 |
Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation
|
|
01 Aug 2019 |
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
|
|
31 Jul 2019 |
TCR2 Therapeutics Announces Partnership with the National Cancer Institute for Phase 1/2 Trial of TC-210
|
|
31 Jul 2019 |
GEMoaB Announces First Patient Dosed With the Affinity-Tailored T-Cell-adaptor GEM3PSCA in a Phase I Study in PSCA-positive Late-Stage Solid Tumors
|
|
31 Jul 2019 |
FDA Approves New Monotherapy Indication for Merck’s KEYTRUDA® (pembrolizumab)
|
|
31 Jul 2019 |
Alligator Bioscience regains global rights from Janssen to CD40 agonistic antibody, ADC-1013 (JNJ-64457107)
|
|
29 Jul 2019 |
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Pathological Complete Response (pCR) in Pivotal Phase 3 KEYNOTE-522 Trial in Patients with Triple-Negative Breast Cancer (TNBC)
|
|
29 Jul 2019 |
European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma
|
|
28 Jul 2019 |
Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the American Society of Retina
|
|
26 Jul 2019 |
Theratechnologies Receives Positive Recommendation From the CHMP for Trogarzo® in the European Union
|
|
26 Jul 2019 |
Novartis receives positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness
|
|
26 Jul 2019 |
Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer
|
|
26 Jul 2019 |
CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer
|
|
26 Jul 2019 |
Janssen Receives CHMP Positive Opinion for Stelara® (ustekinumab) Recommending Approval for the Treatment of Moderately to Severely Active Ulcerative Colitis in the EU
|
|
26 Jul 2019 |
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone for Treatment of Patients with Relapsed and Refractory Multiple Myeloma
|
|
25 Jul 2019 |
Bristol-Myers Squibb Provides Update on Part 2 of CheckMate -227
|
|
25 Jul 2019 |
Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint of Overall Survival
|
|
24 Jul 2019 |
Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation
|
|
24 Jul 2019 |
FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)
|
|
24 Jul 2019 |
FDA Approves Pfizer’s Biosimilar, RUXIENCE™ (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions
|
|
23 Jul 2019 |
FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
|
|
23 Jul 2019 |
Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus
|
|
23 Jul 2019 |
IMFINZI® (durvalumab) US Label Updated With Overall Survival Data in Unresectable, Stage III Non-small Cell Lung Cancer
|
|
22 Jul 2019 |
Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease
|
|
22 Jul 2019 |
Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis
|
